Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: A systematic review by the European League Against Rheumatism systemic vasculitis task force

Annals of the Rheumatic Diseases

Volumn 67, Issue 7, 2008, Pages 1004-1010

  Mukhtyar, C ^a   Flossmann, O ^b   Hellmich, B ^c   Bacon, P ^d   Cid, M ^e   Cohen Tervaert, J W ^f   Gross, W L ^c   Guillevin, L ^g   Jayne, D ^b   Mahr, A ^h   Merkel, P A ^h   Raspe, H ^c   Scott, D ⁱ   Witter, J ^j   Yazici, H ^k   Luqmani, R A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e HOSPITAL CLÍNIC   (Spain)

^f MAASTRICHT UNIVERSITY   (Netherlands)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ Department of Rheumatology   (United Kingdom)

^j CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^k ISTANBUL UNIVERSITY   (Turkey)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; ETANERCEPT; METHOTREXATE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE;

AGE DISTRIBUTION; ARTICLE; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; DRUG DOSE REDUCTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; LOW DRUG DOSE; MAINTENANCE THERAPY; MEDLINE; MICROSCOPIC POLYANGIITIS; MONOTHERAPY; MORBIDITY; OVERALL SURVIVAL; PRIORITY JOURNAL; RELAPSE; REMISSION; SEX DIFFERENCE; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; SYSTEMIC VASCULITIS; WEGENER GRANULOMATOSIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; CHURG-STRAUSS SYNDROME; CYCLOPHOSPHAMIDE; EVIDENCE-BASED MEDICINE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RECURRENCE; REMISSION INDUCTION; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 46849114754     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.071936     Document Type: Article

References (64)

1. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-98.
2. Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999;78:26-37.
3. Aasarod K, Iversen BM, Hammerstrom J, Bostad L, Vatten L, Jorstad S. Wegener's granulomatosis: clinical course in 108 patients with renal involvement. Nephrol Dial Transplant 2000;15:611-8.
4. Guillevin L, Durand-Gasselin B, Cevallos R, Gayraud M, Lhote F, Callard P, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999;42:421-30.
5. Bligny D, Mahr A, Toumelin PL, Mouthon L, Guillevin L. Predicting mortality in systemic Wegener's granulomatosis: a survival analysis based on 93 patients. Arthritis Rheum 2004;51:83-91.
6. Metzler C, Hellmich B, Gause A, Gross WL, de Groot K. Churg Strauss syndrome - successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin Exp Rheumatol 2004;22(6 Suppl 36):S52-61.
7. Hoffman GS, Leavitt RY, Kerr GS, Fauci AS. The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum 1992;35:1322-9.
8. Boomsma MM, Bijl M, Stegeman CA, Kallenberg CG, Hoffman GS, Tervaert JW. Patients' perceptions of the effects of systemic lupus erythematosus on health, function, income, and interpersonal relationships: a comparison with Wegener's granulomatosis. Arthritis Rheum 2002;47:196-201.
9. Koldingsnes W, Nossent H. Predictors of survival and organ damage in Wegener's granulomatosis. Rheumatology (Oxford) 2002;41:572-81.
10. Briedigkeit L, Kettritz R, Gobel U, Natusch R. Prognostic factors in Wegener's granulomatosis. Postgrad Med J 1993;69:856-61.
11. Hellmich B, Flossmann O, Gross WL, Bacon P, Willem Cohen-Tervaert J, Guillevin L, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007;66:605-17.
12. De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:2461-9.
13. Dougados M, Betteridge N, Burmester GR, Euller-Ziegler L, Guillemin F, Hirvonen J, et al. EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis 2004;63:1172-6.
14. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 20033;349:36-44.
15. Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer I, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997;40:2187-98.
16. Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 1996;335:16-20.
17. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 200527;352:351-61.
18. Guillevin L, Cohen P, Mahr A, Arene JP, Mouthon L, Puechal X, et al. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum 2003;49:93-100.
19. Reinhold-Keller E, Kekow J, Schnabel A, Schmitt WH, Heller M, Beigel A, et al. Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. Arthritis Rheum 1994;37:919-24.
20. Sneller MC, Hoffman GS, Talar-Williams C, Kerr GS, Hallahan CW, Fauci AS. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995;38:608-13.
21. Reinhold-Keller E, Beuge N, Latza U, de Groot K, Rudert H, Nolle B, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000;43:1021-32.
22. Bolley R, Mistry-Burchardi N, Samtleben W. Wegener granulomatosis and microscopic polyangiitis. Diagnostic and clinical results in 54 patients with long-term follow-up (in German). Dtsch Med Wochenschr 2000;125:1519-25.
23. Koldingsnes W, Nossent JC. Baseline features and initial treatment as predictors of remission and relapse in Wegener's granulomatosis. J Rheumatol 2003;30:80-8.
24. Luqmani RA, Bacon PA, Beaman M, Scott DG, Emery P, Lee SJ, et al. Classical versus non-renal Wegener's granulomatosis. Q J Med 1994;87:161-7.
25. Gayraud M, Guillevin L, le Toumelin P, Cohen P, Lhote F, Casassus P, et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001;44:666-75.
26. Exley AR, Carruthers DM, Luqmani RA, Kitas GD, Gordon C, Janssen BA, et al. Damage occurs early in systemic vasculitis and is an index of outcome. Q J Med 1997;90:391-9.
27. Reinhold-Keller E, De Groot K, Rudert H, Nolle B, Heller M, Gross WL. Response to trimethoprim/sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease. Q J Med 1996;89:15-23.
28. Haubitz M, Koch KM, Brunkhorst R. Survival and vasculitis activity in patients with end-stage renal disease due to Wegener's granulomatosis. Nephrol Dial Transplant 1998;13:1713-8.
29. Boomsma MM, Stegeman CA, van der Leij MJ, Oost W, Hermans J, Kallenberg CG, et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000;43:2025-33.
30. Fauchais AL, Michon-Pasturel M, Rugale C, Asseray N, Bulckaen H, Queyrel V, et al. Wegener's granulomatosis in the elderly patient. Rev Med Interne 2001;22:127-31.
31. Langford CA, Talar-Williams C, Barron KS, Sneller MC. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 2003;114:463-9.
32. Pavane L, Grasselli C, Chierici E, Maggiore U, Garini G, Ronda N, et al. Outcome and prognostic factors during the course of primary small-vessel vasculitides. J Rheumatol 2006;33:1299-306.
33. Stegeman CA, Tervaert JW, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CG. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994;120:12-7.
34. Adu D, Pall A, Luqmani RA, Richards NT, Howie AJ, Emery P, et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. Q J Med 1997;90:401-9.
35. Haubitz M, Schellong S, Gobel U, Schurek HJ, Schaumann D, Koch KM, et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum 1998;41:1835-44.
36. EUVAS. Completed clinical trials 2007. http://www.vasculitis.org/ comptrials.htm (accessed 27 April 2007).
37. Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002;110:955-63.
38. Pfister H, Ollert M, Frohlich LF, Quintanilla-Martinez L, Colby TV, Specks U, et al. Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood 2004;104:1411-8.
39. Slot MC, Tervaert JW, Boomsma MM, Stegeman CA. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum 2004;51:269-73.
40. Birek R, Schmitt WH, Kaelsch IA, van der Woude FJ. Serial ANCA determinations for monitoring disease activity in patients with ANCA-associated vasculitis: systematic review. Am J Kidney Dis 2006;47:15-23.
41. Hogan SL, Falk RJ, Chin H, Cai J, Jennette CE, Jennette JC, et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 2005;143:621-31.
42. Walton EW. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J 1958;2:265-70.
43. Anderson G, Coles ET, Crane M, Douglas AC, Gibbs AR, Geddes DM, et al. Wegener's granuloma. A series of 265 British cases seen between 1975 and 1985. A report by a sub-committee of the British Thoracic Society Research Committee. Q J Med 1992;83:427-38.
44. Le Thi Huong D, Wechsler B, de Gennes C, Raguin G, Piette JC, Bletry O, et al. Evolutive and prognostic aspects of Wegener's granulomatosis. Rev Rhum Mal Osteoartic 1989;56:583-8.
45. Lane SE, Watts RA, Shepstone L, Scott DG. Primary systemic vasculitis: clinical features and mortality. Q J Med 2005;98:97- 111.
46. Bakoush O, Segelmark M, Torffvit O, Ohlsson S, Tencer J. Urine IgM excretion predicts outcome in ANCA-associated renal vasculitis. Nephrol Dial Transplant 2006;21:1263-9.
47. Lauque D, Cadranel J, Lazor R, Pourrat J, Ronco P, Guillevin L, et al. Microscopic polyangiitis with alveolar hemorrhage. A study of 29 cases and review of the literature. Graupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P). Medicine (Baltimore) 2000;79:222-33.
48. Bourgarit A, Le Toumelin P, Pagnoux C, Cohen P, Mahr A, Le Guern V, et al. Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore) 2005;84:323-30.
49. Solans B, Bosch JA, Perez-Bocanegra C, Selva A, Huguet P, Alijotas J, et al. Churg-Strauss syndrome: outcome and long-term follow-up of 32 patients. Rheumatology (Oxford) 2001;40:763-71.
50. Aasarod K, Iversen BM, Hammerstrom J, Bostad L, Jorstad S. Clinical outcome of patients with Wegener's granulomatosis treated with plasma exchange. Blood Purif 2002;20:167-73.
51. Little MA, Nazar L, Farrington K. Outcome in glomerulonephritis due to systemic small vessel vasculitis: effect of functional status and non-vasculitic co-morbidity. Nephrol Dial Transplant 2004;19:356- 64.
52. Reid AJ, Harrison BD, Watts RA, Watkin SW, McCann BG, Scott DG. Churg-Strauss syndrome in a district hospital. Q J Med 1998;91:219-29.
53. Haas C, Le Jeunne C, Choubrac P, Durand H, Hugues FC. Churg-Strauss syndrome. Retrospective study of 20 cases. Bull Acad Natl Med 2001;185:1113-30.
54. Hattori N, Mori K, Misu K, Koike H, Ichimura M, Sobue G. Mortality and morbidity in peripheral neuropathy associated Churg-Strauss syndrome and microscopic polyangiitis. J Rheumatol 2002;29:1408-14.
55. Vassallo M, Shepherd RJ, Iqbal P, Feehally I. Age-related variations in presentation and outcome in Wegener's granulomatosis. J R Coll Physicians Lond 1997;31:396-400.
56. Bacon PA. The spectrum of Wegener's granulomatosis and disease relapse. N Engl J Med 2005;352:330-2.
57. Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO, et al. Developmentand initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997;40:371-80.
58. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187- 92.
59. Westman KW, Selga D, Isberg PE, Bladstrom A, Olsson H. High proteinase 3-anti-neutrophil cytoplasmic antibody (ANCA) level measured by the capture enzyme-linked immunosorbent assay method is associated with decreased patient survival in ANCA-associated vasculitis with renal involvement. J Am Soc Nephrol 2003;14:2926-33.
60. Allen A, Pusey C, Gaskin G. Outcome of renal replacement therapy in antineutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 1998;9:1258-63.
61. Guillevin L, Lhote F, Gayraud M, Cohen P, Jarrousse B, Lortholary O, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996;75:17-28.
62. Koutantji M, Harrold E, Lane SE, Pearce S, Watts RA, Scott DG. Investigation of quality of life, mood, pain, disability, and disease status in primary systemic vasculitis Arthritis Rheum 2003;49:826-37.
63. Seo P, Min YI, Holbrook JT, Hoffman GS, Merkel PA, Spiera R, et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis Rheum 2005;52:2168-78.
64. Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on ANCA-associated vasculitis. Ann Rheum Dis 2007;66:605-17.